44
Kite’s CD19-targeting CAR-T cell therapy axicabtagene ciloleucel, which received FDA approval in October 2017 to treat B cell lymphomas under the brand name Yescarta, is currently under rewiew by the European Medicines Agency (EMA). The lease of the Dutch site near the airport is not only part of EU commercialisation but of Kite’s global roll out of the second approved autologous CAR-T cell therapy ever, which followed the approval of Novartis Kymriah (tisagenlecleucel) in 2017.
This new European manufacturing facility will enable personalised cell therapies to be manufactured in closer geographic proximity to the patients who will receive…